Current and emerging lupus treatments

American Journal of Managed Care

Volumn 7, Issue 16 SUPPL. OCTOBER, 2001, Pages

  Wallace, D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DEFLAZACORT; DEXAMETHASONE; DICLOFENAC; FLUORINATED STEROID; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; KETOPROFEN; LEFLUNOMIDE; LPJ 394; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PRASTERONE; PREDNISONE; PYRIMIDINE ANTAGONIST; ROFECOXIB; STEROID; UNCLASSIFIED DRUG; VACCINE;

BONE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCOAGULABILITY; MORBIDITY; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; DEHYDROEPIANDROSTERONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; OLIGONUCLEOTIDES;

EID: 0034765974     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. In vitro release and antiinflammatory activity of topical formulations of ketaprofen
2. Double-blind controlled clinical study of the efficacy and tolerability of diclofenac-N-(2-hydroxyethyl)-pyrrolidine lecithin gel compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel in patients with peri and extraarticular inflammatory diseases
3. Is celecoxib sale in SLE with or without sulfa allergy? A pilot study
4. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
5. Anti-malarial drugs: Possible mechanisms of action in autoimmune disease and prospects for drug development
6. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
7. Update on pharmacotherapy of systemic lupus erythematosus
8. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
9. A complex case of hepatitis in a patient with systemic lupus erythematosus
10. Deflazacort - An alterative to prednisolone?
11. Budesonide in the treatment of Crohn's disease: A meta-analysis
12. Low plasma androgens in women with active or quiescent systemic lupus erythematosus
13. Law plasma androgens in women with systemic lupus erythematosus
14. Regulation of murine lymphokine production in vivo. Dehydroepiandrosterone is a natural enhancer of interleukin-2 synthesis by helper T cells
15. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus
16. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial
17. An open study of dehydroepiandrosterone in systemic lupus erythematosus
18. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study
19. GL701 (Prasterone, DHEA) improves systemic lupus erythematosus
20. Improvement in bone mineral density in steroid-treated patients during treatment with GL701 (Prasterone, DHEA)
21. GL701 (Prasterone, DHEA) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus
22. Clinical and pharmacological experience with LJP 394
23. SLE trial shows fewer renal flares in LJP-394: 90-05 trial results
24. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
25. A pilot study of leflunomide in systemic lupus erythematosus (SLE)
26. Benefits of lefunomide (LEF) in systemic drugs lupus erythematosus (SLE) outpatients